Net profit after taxes and minority interest was Rs 266.92 crore for the corresponding period of the previous fiscal, Alkem Laboratories said in a filing to BSE.
Consolidated total income from operations also rose to Rs 1,638.34 crore for the quarter under consideration as against Rs 1,381.95 crore for the year-ago period.
"Despite regulatory headwinds at the start of the financial year in the form of expansion of NLEM (National List of Essential Medicines) list, WPI linked price cuts and downward revision in the ceiling prices of some of our key brands... We have delivered a robust growth in our India business," Alkem CEO Prabhat Agrawal said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
